Schick signs for $5 million credit, loses CFO

Article

In an effort to bolster its business, digital detector developer Schick Technologies of Long Island City, NY, has signed a commitment letter with investment firm Greystone & Co. to provide Schick with a $5-million line of credit, subject to final

In an effort to bolster its business, digital detector developer Schick Technologies of Long Island City, NY, has signed a commitment letter with investment firm Greystone & Co. to provide Schick with a $5-million line of credit, subject to final agreement. Under terms of the deal, Greystone will gain rights to purchase Schick common stock and will fill two seats on the firm’s board of directors. Schick expects the transaction to close by early November.

On the management side, Schick announced the resignation of its CFO, George Rough, and that it has begun the search for his replacement. The company also named John Pauly to the post of chief operating officer. Pauly is president and CEO of PFCM Corp., a professional services company that provides management consulting services worldwide.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.